• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rosiglitazone: a European regulatory perspective.

作者信息

Blind E, Dunder K, de Graeff P A, Abadie E

机构信息

European Medicines Agency, 7 Westferry Circus, Canary Wharf, London E14 4HB, UK.

出版信息

Diabetologia. 2011 Feb;54(2):213-8. doi: 10.1007/s00125-010-1992-5. Epub 2010 Dec 14.

DOI:10.1007/s00125-010-1992-5
PMID:21153629
Abstract
摘要

相似文献

1
Rosiglitazone: a European regulatory perspective.罗格列酮：欧洲监管视角
Diabetologia. 2011 Feb;54(2):213-8. doi: 10.1007/s00125-010-1992-5. Epub 2010 Dec 14.
2
Therapy: The second time as farce: rosiglitazone and the regulators.治疗：第二次闹笑话：罗格列酮和监管者。
Nat Rev Endocrinol. 2011 Jan;7(1):5-6. doi: 10.1038/nrendo.2010.209. Epub 2010 Nov 23.
3
Switching from rosiglitazone: thinking outside the class.从罗格列酮转换治疗：跳出类别思考。
JAMA. 2011 Feb 23;305(8):820-1. doi: 10.1001/jama.2011.193. Epub 2011 Feb 8.
4
The safety of rosiglitazone in the treatment of type 2 diabetes.罗格列酮治疗2型糖尿病的安全性。
Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579.
5
Rosiglitazone and cardiovascular risk: weighing recent evidence.罗格列酮与心血管风险：权衡近期证据
J Cardiometab Syndr. 2007 Fall;2(4):295-6. doi: 10.1111/j.1559-4564.2007.07744.x.
6
Rosiglitazone: seeking a balanced perspective.罗格列酮：寻求平衡的观点。
Lancet. 2007 Jun 2;369(9576):1834. doi: 10.1016/S0140-6736(07)60787-9.
7
The rough road for rosiglitazone.罗格列酮的坎坷之路。
Curr Opin Endocrinol Diabetes Obes. 2008 Apr;15(2):113-7. doi: 10.1097/MED.0b013e3282f8b483.
8
Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.罗格列酮和吡格列酮治疗糖尿病
Am J Health Syst Pharm. 2008 Oct 1;65(19):1846-50. doi: 10.2146/ajhp070659.
9
Cardiovascular safety of rosiglitazone.罗格列酮的心血管安全性。
Lancet. 2007 Jun 16;369(9578):1995-1996. doi: 10.1016/S0140-6736(07)60824-1.
10
Type 2 diabetes, thiazolidinediones, and cardiovascular risk.2型糖尿病、噻唑烷二酮类药物与心血管风险。
Br J Gen Pract. 2009 Jul;59(564):520-4. doi: 10.3399/bjgp09X453440.

引用本文的文献

1
Discovery by Virtual Screening of an Inhibitor of CDK5-Mediated PPARγ Phosphorylation.通过虚拟筛选发现CDK5介导的PPARγ磷酸化抑制剂
ACS Med Chem Lett. 2022 Mar 11;13(4):681-686. doi: 10.1021/acsmedchemlett.1c00715. eCollection 2022 Apr 14.
2
Future Perspective of Diabetic Animal Models.糖尿病动物模型的未来展望。
Endocr Metab Immune Disord Drug Targets. 2020;20(1):25-38. doi: 10.2174/1871530319666190626143832.
3
Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations.糖尿病和糖尿病肾病中的精准医学：监管考虑因素。

本文引用的文献

1
Rosiglitazone: what went wrong?罗格列酮：问题出在哪里？
BMJ. 2010 Sep 6;341:c4848. doi: 10.1136/bmj.c4848.
2
Licensing drugs for diabetes.糖尿病药物的许可
BMJ. 2010 Sep 6;341:c4805. doi: 10.1136/bmj.c4805.
3
Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population.在管理式医疗人群中接受噻唑烷二酮类药物治疗的患者发生心血管事件和全因死亡率的风险。
Diabetes Obes Metab. 2018 Oct;20 Suppl 3(Suppl Suppl 3):19-23. doi: 10.1111/dom.13453.
4
The European Medicines Agency's approval of new medicines for type 2 diabetes.欧洲药品管理局批准用于 2 型糖尿病的新药。
Diabetes Obes Metab. 2018 Sep;20(9):2059-2063. doi: 10.1111/dom.13349. Epub 2018 May 30.
5
A Data-Driven Approach to Predicting Successes and Failures of Clinical Trials.基于数据驱动的临床试验成败预测方法。
Cell Chem Biol. 2016 Oct 20;23(10):1294-1301. doi: 10.1016/j.chembiol.2016.07.023. Epub 2016 Sep 15.
6
Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.新型抗糖尿病药物心血管结局试验的见解：我们学到了什么？行业视角。
Curr Diab Rep. 2015 Nov;15(11):87. doi: 10.1007/s11892-015-0663-9.
7
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes.β细胞功能在2型糖尿病治疗中的重要性。
J Clin Med. 2014 Aug 14;3(3):923-43. doi: 10.3390/jcm3030923.
8
β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.β 细胞功能障碍：在 2 型糖尿病的预防和管理中的关键作用。
World J Diabetes. 2015 Feb 15;6(1):109-24. doi: 10.4239/wjd.v6.i1.109.
9
The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies.使用非胰岛素类降糖药物相关的心力衰竭风险：已发表观察性研究的系统评价和荟萃分析
BMC Cardiovasc Disord. 2014 Sep 26;14:129. doi: 10.1186/1471-2261-14-129.
10
Identifying plausible adverse drug reactions using knowledge extracted from the literature.利用从文献中提取的知识识别可能的药物不良反应。
J Biomed Inform. 2014 Dec;52:293-310. doi: 10.1016/j.jbi.2014.07.011. Epub 2014 Jul 19.
Circ Cardiovasc Qual Outcomes. 2010 Sep;3(5):538-45. doi: 10.1161/CIRCOUTCOMES.109.911461. Epub 2010 Aug 24.
4
Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.罗格列酮再探讨：心肌梗死风险与心血管死亡率的最新荟萃分析
Arch Intern Med. 2010 Jul 26;170(14):1191-1201. doi: 10.1001/archinternmed.2010.207.
5
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.在接受罗格列酮或吡格列酮治疗的老年医疗保险患者中，急性心肌梗死、中风、心力衰竭和死亡的风险。
JAMA. 2010 Jul 28;304(4):411-8. doi: 10.1001/jama.2010.920. Epub 2010 Jun 28.
6
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.罗格列酮用于2型糖尿病口服联合治疗的心血管结局评估（RECORD）：一项多中心、随机、开放标签试验
Lancet. 2009 Jun 20;373(9681):2125-35. doi: 10.1016/S0140-6736(09)60953-3. Epub 2009 Jun 6.
7
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.2型糖尿病高血糖的医学管理：治疗起始与调整的共识算法：美国糖尿病协会和欧洲糖尿病研究协会的共识声明
Diabetologia. 2009 Jan;52(1):17-30. doi: 10.1007/s00125-008-1157-y. Epub 2008 Oct 22.
8
Patient-important outcomes in diabetes--time for consensus.糖尿病患者重要结局——达成共识的时候了。
Lancet. 2007 Sep 29;370(9593):1104-6. doi: 10.1016/S0140-6736(07)61489-5.
9
The rosiglitazone story--lessons from an FDA Advisory Committee meeting.罗格列酮事件——美国食品药品监督管理局咨询委员会会议的教训
N Engl J Med. 2007 Aug 30;357(9):844-6. doi: 10.1056/NEJMp078167. Epub 2007 Aug 8.
10
The record on rosiglitazone and the risk of myocardial infarction.罗格列酮与心肌梗死风险的记录。
N Engl J Med. 2007 Jul 5;357(1):67-9. doi: 10.1056/NEJMe078116. Epub 2007 Jun 5.